Aridis Pharmaceuticals (Aridis Pharmaceuticals) Debt-to-Equity : -0.41 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Debt-to-Equity?

Aridis Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $3.99 Mil. Aridis Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.85 Mil. Aridis Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-11.80 Mil. Aridis Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2023 was -0.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aridis Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ARDS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.64 Med: -0.32 Max: -0.06
Current: -0.41

During the past 7 years, the highest Debt-to-Equity Ratio of Aridis Pharmaceuticals was -0.06. The lowest was -0.64. And the median was -0.32.

ARDS's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs ARDS: -0.41

Aridis Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Aridis Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals Debt-to-Equity Chart

Aridis Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

-0.08

-0.46

-0.25

Aridis Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															-0.39	-0.25	-0.14	-0.42	-0.41

Competitive Comparison of Aridis Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Aridis Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aridis Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aridis Pharmaceuticals's Debt-to-Equity falls into.

Aridis Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aridis Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.838	+	1.292)	/	-24.232
	=	-0.25

Aridis Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.986	+	0.854)	/	-11.802
	=	-0.41

Aridis Pharmaceuticals (OTCPK:ARDS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aridis Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aridis Pharmaceuticals (Aridis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

983 University Avenue, Building B, Los Gatos, CA, USA, 95032

Website

https://www.aridispharma.com

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

Executives

Fibrosis Foundation Cystic	10 percent owner	4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri	officer: Chief Medical Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Vu Truong	director, 10 percent owner, officer: CEO, CSO, Director	5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer	director, 10 percent owner	5941 OPTICAL CT., SAN JOSE CA 95138
John F Hamilton	director	1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak	officer: Chief Financial Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland	officer: Chief Financial Officer	C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer	officer: Chief Medical Officer	5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo	director
Shawn Lu	director	C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin	director	5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025